{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T13:25:20Z","timestamp":1746710720046,"version":"3.40.5"},"reference-count":33,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:p>Cytokine dermatitis is a well-known and common clinical adverse effect of imiquimod 5% cream (Aldara, 3M). Data from initial Phase III clinical trials reveal a minority of study drug patients experience systemic adverse effects, including fever, arthralgia, headache, myalgia, and lymphadenopathy. These adverse effects are caused, presumably, from increased absorption of study drug over the area of dermatitis, leading to systemic cytokine release. Furthermore, the incidence of systemic reactions was rarely statistically increased above control patients. We describe herein a case of severe cytokine dermatitis in a 2-year-old female patient treated with daily imiquimod for molluscum contagiosum who subsequently developed febrile seizure. We believe this to be the first reported case of seizure associated with imiquimod 5% cream (Aldara, 3M) in a pediatric setting.<\/jats:p>","DOI":"10.1542\/peds.2011-0936","type":"journal-article","created":{"date-parts":[[2012,1,5]],"date-time":"2012-01-05T20:00:59Z","timestamp":1325793659000},"page":"e519-e522","source":"Crossref","is-referenced-by-count":9,"title":["Cytokine Dermatitis and Febrile Seizure From Imiquimod"],"prefix":"10.1542","volume":"129","author":[{"given":"J. Suzanne","family":"Mosher","sequence":"first","affiliation":[{"name":"Harvard Vanguard Medical Associates, Watertown, Massachusetts; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[{"name":"Northwestern University, Feinberg School of Medicine, Dermatology & Aesthetics of Wicker Park, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2012,2,1]]},"reference":[{"issue":"5","key":"2021120903091892000_B1","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jaad.2003.12.010","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials","volume":"50","author":"Lebwohl","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2021120903091892000_B2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jaad.2003.11.066","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies","volume":"50","author":"Geisse","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"2021120903091892000_B3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1034\/j.1600-0536.2001.440501.x","article-title":"Contact dermatitis from topical antiviral drugs","volume":"44","author":"Holdiness","year":"2001","journal-title":"Contact Dermat"},{"issue":"1","key":"2021120903091892000_B4","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1016\/j.jaad.2004.10.858","article-title":"Topical application of imiquimod and associated fever in children","volume":"52","author":"Campanelli","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2021120903091892000_B5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0168-8278(96)80185-1","article-title":"Seizures during alpha interferon therapy","volume":"24","author":"Shakil","year":"1996","journal-title":"J Hepatol"},{"issue":"4","key":"2021120903091892000_B6","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0168-8278(97)80269-3","article-title":"Seizures in children during interferon alpha therapy","volume":"26","author":"Woynarowski","year":"1997","journal-title":"J Hepatol"},{"issue":"1","key":"2021120903091892000_B7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0887-8994(03)00040-7","article-title":"Onset of generalized seizures after intrathecal interferon therapy of SSPE","volume":"29","author":"Caksen","year":"2003","journal-title":"Pediatr Neurol"},{"issue":"1","key":"2021120903091892000_B8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s00415-005-0596-3","article-title":"Persistent BBB disruption may underlie alpha interferon-induced seizures","volume":"252","author":"Pavlovsky","year":"2005","journal-title":"J Neurol"},{"issue":"3","key":"2021120903091892000_B9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0887-8994(01)00380-0","article-title":"Increased frequency of interleukin-1beta (-511) allele 2 in febrile seizures","volume":"26","author":"Virta","year":"2002","journal-title":"Pediatr Neurol"},{"key":"2021120903091892000_B10","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/978-1-4757-6376-8_15","article-title":"Febrile seizures and mechanisms of epileptogenesis: insights from an animal model","volume":"548","author":"Bender","year":"2004","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"2021120903091892000_B11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1535-7511.2005.00053.x","article-title":"Cytokines: a link between fever and seizures","volume":"5","author":"Mazarati","year":"2005","journal-title":"Epilepsy Curr"},{"key":"2021120903091892000_B12"},{"issue":"2","key":"2021120903091892000_B13","first-page":"134","article-title":"Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial","volume":"74","author":"Theos","year":"2004","journal-title":"Cutis"},{"issue":"7","key":"2021120903091892000_B14","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1046\/j.1365-2230.2002.01151.x","article-title":"Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential","volume":"27","author":"Stanley","year":"2002","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"2021120903091892000_B15","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.jaad.2004.01.037","article-title":"Angioedema associated with imiquimod","volume":"51","author":"Barton","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"2021120903091892000_B16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/archderm.140.7.889","article-title":"Localized pemphigus foliaceus induced by topical imiquimod treatment","volume":"140","author":"Lin","year":"2004","journal-title":"Arch Dermatol"},{"issue":"7","key":"2021120903091892000_B17","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1001\/archderm.141.7.908","article-title":"Possible mechanisms in the induction of pemphigus foliaceus by topical imiquimod treatment","volume":"141","author":"Mashiah","year":"2005","journal-title":"Arch Dermatol"},{"issue":"2","key":"2021120903091892000_B18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jaad.2004.06.045","article-title":"Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis","volume":"52","author":"Chakrabarty","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2021120903091892000_B19","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2005.03.040","article-title":"Aphthous ulcers and imiquimod","volume":"53","author":"Zalaudek","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"2021120903091892000_B20","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/00042728-200507000-00011","article-title":"Eruptive epidermoid cysts resulting from treatment with imiquimod","volume":"31","author":"Marty","year":"2005","journal-title":"Dermatol Surg"},{"issue":"4","key":"2021120903091892000_B21","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jaad.2004.10.861","article-title":"Vitiligo-like hypopigmentation associated with imiquimod treatment of genital warts","volume":"52","author":"Brown","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2021120903091892000_B22","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1365-2230.2005.01938.x","article-title":"Generalized exacerbation of psoriasis associated with imiquimod cream treatment of superficial basal cell carcinomas","volume":"31","author":"Rajan","year":"2006","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2021120903091892000_B23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-0960.2004.00060.x","article-title":"Imiquimod: potential risk of an immunostimulant","volume":"45","author":"Benson","year":"2004","journal-title":"Australas J Dermatol"},{"issue":"1223","key":"2021120903091892000_B24","first-page":"U1682","article-title":"Systemic side effects from topical imiquimod","volume":"118","author":"Hanger","year":"2005","journal-title":"N Z Med J"},{"key":"2021120903091892000_B25"},{"issue":"2","key":"2021120903091892000_B26","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jaad.2004.03.022","article-title":"Chronic neuropathic pain associated with imiquimod: report of 2 cases","volume":"52","author":"Yi","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2021120903091892000_B27","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.jaad.2004.02.022","article-title":"Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology","volume":"51","author":"Szeimies","year":"2004","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2021120903091892000_B28","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.141.4.467","article-title":"Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials","volume":"141","author":"Korman","year":"2005","journal-title":"Arch Dermatol"},{"issue":"5","key":"2021120903091892000_B29","first-page":"374","article-title":"Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: interim 2-year results from an ongoing 5-year follow-up study in Europe","volume":"15","author":"Gollnick","year":"2005","journal-title":"Eur J Dermatol"},{"issue":"5","key":"2021120903091892000_B30","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1111\/j.1365-2133.2005.06486.x","article-title":"Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe","volume":"152","author":"Schulze","year":"2005","journal-title":"Br J Dermatol"},{"issue":"11","key":"2021120903091892000_B31","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1258\/0956462011924218","article-title":"Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts\u2014results of an open-label, multicentre Phase IIIB trial","volume":"12","author":"Garland","year":"2001","journal-title":"Int J STD AIDS"},{"key":"2021120903091892000_B32"},{"key":"2021120903091892000_B33"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/129\/2\/e519\/1056736\/peds_2011-0936.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/129\/2\/e519\/1056736\/peds_2011-0936.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T17:07:47Z","timestamp":1639069667000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/129\/2\/e519\/32501\/Cytokine-Dermatitis-and-Febrile-Seizure-From"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,1]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,1]]},"published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2011-0936","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"type":"print","value":"0031-4005"},{"type":"electronic","value":"1098-4275"}],"subject":[],"published":{"date-parts":[[2012,2,1]]}}}